Regenerex Pharma Reports Increased Losses and Deteriorating Financial Position in Latest Filing

Regenerex Pharma, Inc. reported significant financial challenges in its latest 10-Q filing for the six months ending September 30, 2025. The company recorded a net loss of $1,477,596, a substantial increase from the loss of $802,132 during the same period in 2024. This increase in losses is attributed to heightened operating expenses, particularly in research and development, payroll, lease costs, and information technology expenditures. The company has yet to generate any revenue from its operations, maintaining a consistent trend from the previous fiscal year.

The financial position of Regenerex has deteriorated, with total assets decreasing to $617,764 from $1,263,236 as of March 31, 2025. Current liabilities remained stable at approximately $4.9 million, while stockholders' deficit increased to $4,698,800, up from $4,156,205. The company’s cash and equivalents plummeted to $11,659 from $653,025, indicating a critical liquidity situation. The filing also highlighted that the company has incurred an accumulated deficit of $9,620,486, raising concerns about its ability to continue as a going concern.

Strategically, Regenerex has made moves to enhance its product offerings and market presence. The company entered into an agreement to purchase technology platforms for $2.4 million, which has been extended to December 31, 2025, due to unmet sales and investment targets. Additionally, Regenerex is developing managed care agreements with southeastern states to manage Medicaid wound care patients, which could potentially generate annual revenue exceeding $100 million. The company is also negotiating with distributors in the Middle East to expand its market reach.

Operationally, Regenerex has not reported any customer counts or product adoption rates, as it has not yet launched its products. However, the company is preparing to introduce its wound care products, including Xcellderma and Accelerex, in the fourth quarter of its fiscal year ending December 31, 2025. The company’s workforce has expanded, contributing to increased payroll expenses, but specific employee headcount figures were not disclosed in the filing.

Looking ahead, Regenerex's management is focused on securing additional capital to support its operations and product launches. The company acknowledges the uncertainty surrounding its ability to raise sufficient funds and achieve profitability. The management's plans include actively seeking capital to enhance its product offerings and reduce liabilities, although they cannot guarantee success in these endeavors. The company’s future remains contingent on its ability to navigate these financial challenges and execute its strategic initiatives effectively.